Drug intelligence / Profile preview

Excilor

Development stage
Unknown
Lead developer
Oystershell
Modality
Small Molecules
Administration
Topical
01

Overview

Excilor is an over-the-counter topical treatment designed for the management of fungal nail infections (onychomycosis). Developed by Oystershell Laboratories and marketed by Vemedia (part of Cooper Consumer Health), the product is classified as a medical device rather than a pharmacological drug. Its primary mechanism of action is the acidification of the nail microenvironment; by utilizing acetic acid to lower the pH level within the nail plate, it creates a hostile environment that inhibits the growth and proliferation of dermatophytes. The formulation incorporates TransActive or TransActive+ Technology, which facilitates deep penetration of the active ingredients through the dense keratin of the nail without the need for filing. Excilor is available in several formats, including a solution and film-forming versions (Ultra and Forte) that provide sustained delivery of the treatment for up to 24 hours.

Brand names
ExcilorExcilor SolutionExcilor UltraExcilor Forte

Beyond the preview

Go deeper on Excilor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Excilor.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call